TX-OURO
24.4.2024 15:54:31 CEST | Business Wire | Press release
Ouro, a global financial services and technology innovator, and the Real Madrid Football Club today announced a strategic partnership agreement to develop and deliver co-branded financial solutions to fans in key markets globally, including the United States, Mexico, Brazil, Portugal, France and the United Arab Emirates. The alliance makes Ouro the exclusive partner of the men's and women's football teams for the prepaid, debit and credit card product categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424106690/en/
The signing event held April 15 in Madrid with Ouro founders Bertrand Sosa and Roy Sosa and Emilio Butragueño, Real Madrid’s Director of Institutional Relations. (Photo: Business Wire)
From the April 15 signing event in Madrid, Emilio Butragueño, Real Madrid’s Director of Institutional Relations, commented, “It’s hugely gratifying. They are leaders in financial services who will partner with us in countries around the world. We share a commitment to values like constant reinvention and trying to get better everyday that are as fundamental to our organizations as integrity. We look forward to an enduring and rewarding partnership.”
As an official partner to Real Madrid in these countries, Ouro will unite the Real Madrid brand and Madridista loyalty program benefits with Ouro branded products and their unique functionalities – this includes Ouro’s flagship Netspend brand which pioneered prepaid debit for underserved consumers across the U.S., and its more recently developed X World Wallet that offers a multi-currency wallet and payments app for mobile, multicultural consumers.
“We are honored to join forces with such a storied and beloved global brand to make financial empowerment products more accessible to more people,” said Bertrand Sosa, president and chief brand officer, Ouro. “This unique opportunity to help people take their money further so they can experience more of what they love is the motivation behind our work, and to have Real Madrid collaborate with us to deliver even more value to such a passionate fan base is very special.”
By joining sports loyalty with financial solutions, Ouro and Real Madrid aim to deepen the Madridistas’ connection with their club, maximize the value of their money and promote financial responsibility and accessibility. The partnership also supports Ouro’s strategic focus on innovation, growth, and expansion to global markets.
“We are proud to announce our partnership with Real Madrid, a global icon that shares our values of excellence, winning spirit, solidarity, and humility,” added Roy Sosa, Ouro CEO and Co-founder. “Today we start a movement that transcends sports. Together, we will empower millions of fans and customers to achieve their financial goals and turn their dreams into reality.”
The partnership will soon launch a co-branded Netspend card featuring the Real Madrid brand in the U.S. in anticipation of the team’s upcoming U.S. Summer Tour.
The partners have also started joint development of a co-branded financial product combining the loyalty benefits of the Madridista Club membership with a digital multi-currency wallet they will begin rolling out to fans around the world later this year. Loyal Real Madrid fans can expect these payment products to bring them even closer to the action, with special access to discounts and experiences at the point of sale and beyond.
Fans who want to be among the first to know about availability where they live can now join the waitlist at ouro.com/realmadrid.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro's financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit ouro.com.
About Real Madrid
Real Madrid C.F. is a sport entity with 122 years of history. It is the club with the most European Cups of both football (14) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 534 million followers on social media, being the strongest football brand in the world according to Brand Finance for the second year in a row and also the highest earning football club in the world in the 22-23 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424106690/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom